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Trachoma is caused by Chlamydia trachomatis and is a leading cause of blindness worldwide. Mass distribution of azithromycin
(AZM) is part of the strategy for the global elimination of blinding trachoma by 2020. Although resistance to AZM inC. trachomatis
has not been reported, there have been concerns about resistance in other organisms when AZM is administered in community
settings. We identified studies that measured pneumococcal prevalence and resistance to AZM following mass AZM provision
reported up to 2013 in Medline and Web of Science databases. Potential sources of bias were assessed using the Cochrane Risk of
Bias Tool. A total of 45 records were screened, of which 8 met the inclusion criteria. We identified two distinct trends of resistance
prevalence, which are dependent on frequency of AZM provision and baseline prevalence of resistance. We also demonstrated
strong correlation between the prevalence of resistance at baseline and at 2-3 months (𝑟 = 0.759). Although resistance to AZM in
C. trachomatis has not been reported, resistance to this commonly used macrolide antibiotic in other diseases could compromise
treatment. This should be considered when planning long-term trachoma control strategies.
1. Introduction
Trachoma, caused by ocular infection with Chlamydia tra-
chomatis, is the leading contagious cause of blindness glob-
ally. Estimations by Mariotti et al. in 2008 suggested there
were 40.6 million people worldwide suffering from active
trachoma, leading to trichiasis in 8.2 million [1]. Trachoma is
responsible for visual impairment in 2.2 million and clinical
blindness in 1.2 million individuals [2].
Trachoma, a Neglected Tropical Disease (NTD), spreads
efficiently within households and in areas with poor sanita-
tion and hygiene [3]. The Musca sorbens fly, which breeds
on human faeces, may also act as a vector for transmis-
sion. The disease is highly correlated with poverty, lack of
clean water for washing, and limited access to healthcare.
Trachoma infections occur mainly in children aged 1 to 5,
who act as reservoir for the bacterium. In older age groups,
the development of immunity limits infection, although
reduced exposure as a result of behavioural change also
contributes to the declining prevalence of infection with age
[4].
Repeated ocular infections by Chlamydia trachomatis
inflame the eyelids, leading to scarring of the conjunctival
lining of the upper eyelid. When the lid margin is distorted,
eyelashes turn inwards touching the eye surface, termed
entropion trichiasis. Unresolved repeated abrasions of the
cornea contribute to disabling pain, corneal opacification,
and ultimately the loss of vision [1, 5].
In 1997, WHO established the Alliance for Global Elimi-
nation of Trachoma by the year 2020 (GET 2020), a partner-
ship with the aim to eliminate blindness caused by trachoma
[6]. The GET 2020 alliance recommends interventions for
trachoma control, known by the acronym SAFE, which
stands for surgery for trichiasis, antibiotics, facial cleanliness,
and environmental improvement, including clean water and
latrines.
The aim of antibiotic use is not only to treat the affected
patients, but also to limit disease transmission to others.
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It was estimated that the ultimate intervention goals would
require antibiotic treatment for some 340 million people and
trichiasis surgeries for 8.2 million [1, 5].
There are concerns about the possibility of antibiotic
resistance, especially among bacterial pathogens such as
Streptococcus pneumoniae, which could potentially under-
mine the SAFE strategy. Invasive pneumococcal diseases
associatedwith Streptococcus pneumoniae are amajor cause of
morbidity and mortality worldwide, resulting in around half
a million deaths in children under 5 in 2008, mostly in devel-
oping countries [7]. Invasive pneumococcal diseases include
pneumonia, meningitis, and bacteraemia. Azithromycin is
commonly used for the treatment of community-acquired
pneumonia in adults and clinical cure is compromised in
patients infected with resistant strains [8].
Resistance to azithromycin (AZM) has not been docu-
mented in isolates of Chlamydia trachomatis [9] following
mass treatment in trachoma control programmes. However,
correlation between macrolide use and resistance in Strepto-
coccus pneumoniae has been well documented [10, 11]. For
example, a randomized controlled trial by Malhotra-Kumar
et al. showed a causal effect between AZM use in individuals
and resistance in streptococci, which remained significant
until 6 months after treatment [11].
Several studies have been conducted to examine the
possibility of antibiotic resistance in Streptococcus pneumo-
niae after mass trachoma treatment with oral AZM. Here,
we attempt to summarize their findings and quantify the
impact of AZM. This systematic review considers studies
that involved participants of any age in trachoma-affected
regions, who received oral azithromycin as part of trachoma
eradication program, where outcome measures included
Streptococcus pneumoniae presence and antibiotic resistance
detected from nasopharyngeal swabs of participants.
2. Methods
Searches were performed by Derek K-H. Ho and Chris-
tian Sawicki on electronic databases Medline and Web of
Science up to 23rd of January 2014. Search terms included
azithromycin, Zithromax©, resistance, resistant, and tra-
choma. The search string was “(azithromycin or zithromax)
AND resistan∗ AND trachoma.” No limits were applied for
language or year. Cochrane andDARE (Database of Abstracts
of Reviews of Effectiveness) databases were also consulted
[12, 13].
2.1. Eligibility Criteria
2.1.1. Inclusion Criteria. Studies of community-wide tra-
choma treatment with azithromycin that measured the
prevalence of Streptococcus pneumoniae carriage and AZM
sensitivity based on nasopharyngeal swabs were included in
the analysis. Selection criteria for swabbed individuals should
be clearly outlined. Resistance status was based on minimum
inhibitory concentration values as per test kit instructions.
Any year, language, or length of follow-up were considered.
Participants who received other drugs such as tetracycline
ointment or took azithromycin in forms other than oral were
not included in the analysis.
2.1.2. Outcome Measures. Primary outcome measure is the
prevalence of antibiotic resistance to azithromycin in Strep-
tococcus pneumoniae isolated from nasopharyngeal swabs of
study participants before and after community-wide admin-
istrations.
Secondary outcome measure is the prevalence of Strepto-
coccus pneumoniae carriage in nasopharyngeal samples from
participants.
2.1.3. Exclusion Criteria. The following studies were
excluded: reports of antibiotic resistance in species other
than S. pneumoniae; use of azithromycin other than for
treatment and prevention of trachoma; mathematical
modeling; surveillance reports; review articles; case reports
or series with a study size of less than 50; studies without a
consistent laboratory protocol for resistance testing; studies
without sufficient information on the number of samples
tested.
Eligibility assessment was performed by Derek K-H. Ho
and Christian Sawicki independently, the results of which
were then checked by Nicholas Grassly.
2.2. Data Extraction Process. Derek K-H. Ho extracted the
data from the studies that met the eligibility criteria, and then
recorded the primary and secondary outcome measures as
well as the participant numbers and demography, geographic
areas, azithromycin regimes, and its background usage in the
regions. The data was then examined by Nicholas Grassly.
Derek K-H. Ho also assessed the included studies for risk of
bias using the Cochrane Risk of Bias Tool [14].
2.3. Statistical Analysis. Odds ratios (OR) were calculated
and pooled across studies using theMantel-Haenszel random
effects model implemented in Review Manager 5.2. Results
were summarized in forest plots and heterogeneity across
studies assessed using the 𝐼2 statistic [15]. Exact 95% con-
fidence intervals on proportions were calculated using the
Clopper-Pearson method.
For the purpose of analysis, we defined resistance to
azithromycin as reported in the studies.
3. Results
Searches on Medline and Web of Science provided 28 and
43 results, respectively, giving a total of 71 citations. After
adjusting for duplicates, 45 remained. Of these, 18 studies
were discarded as they did not fit the inclusion criteria,
having reviewed their titles and abstracts. The full text of the
remaining 27 citations was retrieved and examined in detail,
and 19 of them were rejected by the exclusion criteria. A
total of 8 remaining studies were identified for inclusion in
the systematic review [16–23]. All 8 studies were published
in English. No unpublished data were sought. The selection
process is depicted as the PRISMA flow diagram (Figure 1).
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Figure 1: PRISMA flow diagram.
3.1. Characteristics of Included Studies
3.1.1. Participants. The included studies involved around
10000 participants in total. 6 were community-based studies
and 2 were individual-based studies (Table 1). One study
[23] recruited children under 5, three studies [17, 19, 20]
recruited 1- to 10-year-olds, two studies [18, 21] recruited
all nonpregnant residents over 1 year old, and two studies
[16, 19] recruited childrenwith trachoma and their household
contacts. In four studies [18, 20–22], participants who were
ineligible, including pregnant women, infants less than 1 year
old, and individuals allergic to AZM, were given tetracycline
ointments instead.
3.1.2. Intervention. All studies took place in less-developed
countries or disadvantaged communities. Two studies took
place in Ethiopia [21, 22], three studies took place in Nepal
[17, 19, 20], and two studies took place in Tanzania [18, 23].
One study targeted the aboriginal community in Northern
Australia [16]. Four studies included untreated control arms
[20–23].
There was considerable variation in the administration
regimes used; azithromycin was administered once only at
the beginning of five of the studies [16–19, 23], 3monthly for 4
times in one study [22], annually for 3 times in one study [20],
and biannually for 6 times in one study [21]. AZMdosage was
mentioned in all but one study [23]. All specified the dosage
as 20mg/kg, while two studies also administered 1 gram for
adults [19, 21].
3.1.3. Sampling. Therewere largely two categories of sampling
criteria for the eight included studies: random selection from
a predefined age range [17, 19, 21–23] or all children within
a specified age range [16, 18, 20]. Only one study specifically
sampled children with trachoma [16]; other studies did not
specify disease status.
3.2. Outcomes
3.2.1. Primary: What Is the Effect of Azithromycin Treat-
ment on Antibiotic Resistance among S. pneumoniae Isolates
from the Nasopharynx? The resistance status of Streptococcus
pneumoniae to AZM was tested using different commercial
tests: E-test© strips (AB Biodisk, Sweden and USA) [16, 18,
19, 22, 23] and broth dilution Sensititre© MIC plates (Trek
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Figure 2: (a) Prevalence of azithromycin resistance amongst pneumococcus carriers plotted against time in studies with low-frequency
azithromycin provision. The error bars show 95% confidence intervals about the proportions. (b) Prevalence of azithromycin resistance
amongst pneumococcus carriers plotted against time in studies with high-frequency azithromycin provision or high baseline resistance. The
error bars show 95% confidence intervals about the proportions.
Diagnostics Inc., USA) [20, 21]. One studymentioned the use
of broth dilution MIC testing without specifying whether it
was a commercial product [17].
Resistance status was determined by the MIC values as
per test kit instructions; this was explicitly stated in six studies
[16, 18–20, 22, 23]. The two remaining studies [17, 21] made
reference to National Committee for Clinical Laboratory
Standards, USA [24], and Clinical and Laboratory Standards
Institute, USA [25], respectively.
The sampling process and subsequent transportation to
laboratories were described in all studies. However, only four
of the studies described the process of masking samples to
laboratory workers [20–23].
Five studies [16–18, 22, 23] measured the baseline preva-
lence of resistance before AZM administration. The eight
studies performed measurements at various time points after
the antibiotic therapy, varying from once only at month 3 in
Skalet’s study [22] to month 6, year 1, and year 2 in Haug’s
study [21].
As previously mentioned, Haug 2010 and Skalet 2010,
both based in Ethiopia, administered the antibiotic at higher
frequencies, biannually and quarterly, respectively, than the
rest of the included studies.
All but two studies (Haug 2010 and Cole 2013) recorded
low baseline prevalence of S. pneumoniae resistance to AZM
(0% to 5.3% of isolates), which rose within three weeks
following drug intake (0% to 54.6% of isolates) (Figure 2(a)).
These studies showed the resistance figures dropping below
20% by 6 months and below 5% by 12 months.
Haug, Skalet, and Coles’ studies showed much
higher resistance rates at over 75% by 6 months [21–23]
(Figure 2(b)). For Haug 2010 and Skalet 2010 studies, this
was likely due to the more frequent AZM administration as
discussed earlier, whilst, for Coles 2013 study, similarly high
resistance values at baseline have also been demonstrated
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Figure 3: Correlation between prevalence of AZM resistance at
baseline and months 2-3.
by the control group. These three studies appeared to
display similar trends in the prevalence of resistance, with
a prolonged peak of resistance at around 80% even at 6
months.
Five of the studies took baseline measurements [16–18,
22, 23] and four of the studies had a control arm [20–23].
However, due to the fundamental differences in the nature of
these studies, both in terms of frequencies of AZM provision
and varied baseline resistance, we did not combine the data
for meta-analysis. It is of particular note that Coles 2013
demonstrated a high baseline resistance of 36% even without
the prior dosing as in Haug 2010 study.
Examining the five studies where baseline resistance
was recorded, the prevalence of resistance at months 2 to
3 appeared highly correlated with that of baseline, with a
correlation coefficient of 0.759 (Figure 3).
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Figure 4: Prevalence of pneumococcal carriage, demonstrating the
effect of azithromycin administration. The error bars show 95%
confidence intervals about the proportions.
3.2.2. Secondary: What Is the Effect of Azithromycin Admin-
istration on the Prevalence of Nasopharyngeal Carriage of S.
pneumoniae? A variety of tests have been used to demon-
strate the presence of the pathogen. These included Strep-
tococcus selective media [19, 21, 22], morphology [16, 18],
observation for 𝛼-haemolysis [18, 19], optochin susceptibility
[16, 18, 19, 21–23], and bile solubility test [18, 19, 21, 22]. Two
studies only described the use of media and sample freezing,
but not the type of test used [17, 20].
Prevalence of pneumococcal carriage in six of the eight
studies ranged from 68% to 85% initially (Figure 4) and fell
within days after AZM administration, returning to original
values from 2 months onwards. Batt’s and Coles’ studies
remained below 15% and 52% prevalence throughout the 6
months of their study periods, respectively.
3.3. Risk of Bias in Included Studies
3.3.1. Selection Bias. Two of the studies [16, 19], instead of
providing “blanket” AZM coverage to population, adminis-
tered the antibiotic only to individuals suffering from active
disease and their household contacts. The WHO simplified
trachoma grading scale was used in one of these studies [19],
but the number of assessors and the degree of their agreement
were unknown. Leach did not report the criteria used at
screening [16]. For studies with control groups, Skalet and
Haug described the randomization process in treatment and
control group allocations. This was absent in Gaynor’s and
Coles’ studies; however. In Coles’ study, the treated villages
were chosen for their high trachoma prevalence (>10%),
whilst the ineligible villages served as control group. Gaynor
appeared to have included two randomly selected untreated
villages only at the end of the study [20].
3.3.2. Performance Bias. There was no masking of the study
personnel, as the use of placebo was not mentioned in any of
the included studies.
3.3.3. Detection Bias. Assessments of nasopharyngeal strep-
tococci carriage and antibiotic resistance are relatively easy
to mask, as it is straightforward to anonymize laboratory
samples.Three out of eight studies [20–22] reported masking
of the outcome assessors (the laboratory workers) to the
nasopharyngeal samples.
3.3.4. Selective Reporting. Five out of eight studies reported
sampling at baseline (i.e., before AZM was administered).
Six studies reported outcomes at 6 months. The furthest
follow-up point was 2 years. There was no suggestion from
the published reports that the outcomes at any other time
points were undisclosed due to selective reporting, although
the lack of sampling at baseline made results interpretation
more difficult due to the heterogeneity in the prevalence of
resistance in different regions.
3.3.5. Limitations of the Study. There were insufficient studies
to rigorously assess reporting bias using funnel plots. We
judged that there was no selective reporting of outcomes
because the data was presented in full in all the included
studies.
We included all studies irrespective of the language of
publication; however, we cannot exclude the possibility that
relevant studies published in languages other than English
were not picked up in the initial search or that studies with
negative findings were published in less accessible journals.
3.3.6. Other Potential Sources of Bias. Background use of
AZM or other erythromycins in the study regions could
also render results less reliable, as the selection pressure
would have been present prior to the studies. For the two
studies in western Nepal [17, 20], around 3000 children were
administered azithromycin as part of a clinical trial in 1998
[26]. For Coles’ study, the reported use of (unspecified) drugs
to treat suspected infections in the 30 days prior to study
was over 65%. However, comparison with baseline or with a
control arm in these studies mitigates against bias introduced
by the use of antibiotics outside the study intervention. All
other studies reported minimal background AZM use.
Azithromycin coverage also varies in different trials, as
denoted in Table 1. For example, Batt administered AZM to
all nonpregnant residents over 1 year old [18], while Coles
administered the antibiotic only to children under 5 years old
[23].
4. Discussion
Streptococcus pneumoniae is the most common causative
pathogen for community-acquired pneumonia (CAP) [27].
Published guidelines from the Infectious Diseases Society of
America (IDSA), European Society of Clinical Microbiology
and Infectious Diseases (ESCMID), and British Thoracic
Society (BTS) all reaffirm the role of macrolide as part of the
initial empirical treatment for CAP in both outpatient and
hospital settings [28–30].This is particularly so in the US due
to the higher prevalence of atypical organisms, whilst more
emphasis is placed on penicillins in Europe and UK.
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An European study on outpatient antibiotics use demon-
strated a significant positive correlation between the volume
of penicillin consumption in 19 countries and the prevalence
of antibiotic resistance in S. pneumoniae [31]. This is of
significance, because there may come a time for routine
macrolide use when pneumococcal infections become com-
monly penicillin resistant.
A study that compared between annual and twice-yearly
azithromycin regimes demonstrated that while a twice-yearly
treatment can hasten the mean elimination time of ocular
chlamydial infection by 7.5 months, the two groups showed
no difference in disease prevalence from 18 months onwards
[32].
Our systematic review faced some challenges as a result
of limitations in the included studies. Three studies did
not measure the baseline pneumococcal prevalence and
antibiotic resistance.This made it difficult to prove that AZM
provision resulted in any change. Four studies did not include
a control armandonly 2 studies followedup their participants
beyond 6months, withGaynor 2003measuring 0% resistance
to AZM among isolates at 1 year and Haug measuring 30.6%,
which was similar to the baseline value of 28.2%. In terms of
the strength of the included studies, all were cohort studies
except Skalet 2010 and Haug 2010, which were randomized
controlled trials.
A recent mathematical modeling study, based on the
study data from Haug 2010, estimated that within 5 years
of the last antibiotic dose there would be a 95% chance of
macrolide resistance being eliminated by intraspecies compe-
tition [33]. However, it has also been suggested that sustained
antibiotic use below a critical threshold may encourage the
persistence of antimicrobial drug resistance [34].
Despite these limitations, it appears that in communities
where baseline resistance to azithromycin in pneumococcus
is low, mass AZM administration increased resistance only
transiently, with the proportion of resistant cases gradu-
ally reducing as measurements were taken at further time
points. A lack of long-lasting pneumococcal resistance may
be somewhat reassuring for azithromycin-based trachoma
eradication programs.
We however also noted two studies [21, 23] that demon-
strated high baseline and subsequent antibiotic resistance in
Streptococcus; one is the only study that implemented a high-
intensity regimen for a prolonged period (twice a year for
three years) [21], whilst the population examined in the other
study appeared to have high background antibiotic use (65%–
73% in control and treatment groups) [23].These results from
the field may give us an insight as to the potential adverse
outcome when a critical threshold of antibiotic use in the
region is exceeded. Our analysis, which showed a certain level
of correlation of resistance prevalence between baseline and
subsequent time point with a coefficient of 0.759, appears to
be in agreement with this hypothesis.
Woolhouse and Farrar recently reiterated the importance
of global efforts in combating antimicrobial resistance, with
one of the possible solutions being the investigation of dosing
regimens that can stall resistance development [35]. Health
authorities in trachoma-affected regions should therefore be
mindful of the selective pressure asserted by mass antibiotic
use when implementing the SAFE strategy.
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